1. Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification.
Nat Rev Nephrol 6:2010;494–499.
2. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.
Nat Rev Nephrol 8:2012;634–642.
3. Gale D.P., de Jorge E.G., Cook H.T., Martinez-Barricarte R., Hadjisavvas A., McLean A.G., Pusey C.D., Pierides A., Kyriacou K., Athanasiou Y., Voskarides K., Deltas C., Palmer A., Frémeaux-Bacchi V., de Cordoba SR, Maxwell P.H., Pickering M.C.. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.
Lancet 376:2010;794–801.
4. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
Kidney Int 82:2012;465–473.
5. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.
Semin Nephrol 31:2011;341–348.
6. Ann Intern Med.
7. Servais A., Frémeaux-Bacchi V., Lequintrec M., Salomon R., Blouin J., Knebelmann B., Grünfeld J.P., Lesavre P., Noël L.H., Fakhouri F.. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
J Med Genet 44:2007;193–199.
8. Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, Cramer C, Nester CM, Smith RJ. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Clin J Am Soc Nephrol 6:2011;1009–1017.
9. Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D׳Agati VD. Pathology after eculizumab in dense deposit disease and C3 GN.
J Am Soc Nephrol 23:2012;1229–1237.
10. Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ. Eculizumab and recurrent C3 glomerulonephritis.
Pediatr Nephrol 28:2013;1975–1981.
11. Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, Pluthero F, Licht C. Eculizumab and refractory membranoproliferative glomerulonephritis.
N Engl J Med 366:2012;1165–1166.
12. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D׳Agati VD, Canetta PA, Radhakrishnan J, Appel GB. Eculizumab for dense deposit disease and C3 glomerulonephritis.
Clin J Am Soc Nephrol 7:2012;748–756.
13. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D׳Agati VD. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.
Clin J Am Soc Nephrol 4:2009;22–32.
14. Appel G.B., Cook H.T., Hageman G., Jennette J.C., Kashgarian M., Kirschfink M., Lambris J.D., Lanning L., Lutz H.U., Meri S., Rose N.R., Salant D.J., Sethi S., Smith R.J., Smoyer W., Tully H.F., Tully S.P., Walker P., Welsh M., Würzner R., Zipfel P.F.. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.
J Am Soc Nephrol 16:2005;1392–1403.
15. Bennett WM, Fassett RG, Walker RG, Fairley KF, d׳Apice AJ, Kincaid-Smith P. Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease.
Am J Kidney Dis 13:1989;469–476.
16. Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk.
Kidney Int 69:2006;504–511.
17. Somers M, Kertesz S, Rosen S, Herrin J, Colvin R. Palacios de Carreta N, Kim M: Non-nephrotic children with membranoproliferative glomerulonephritis: are steroids indicated?
Pediatr Nephrol 9:1995;140–144.